Lumify, Besivance shown to inactivate COVID-19
Click Here to Manage Email Alerts
Lumify and Besivance showed complete inactivation of COVID-19 in an investigational study, researchers reported at the Ocular Microbiology and Immunology Group annual meeting.
They evaluated two benzalkonium chloride preserved eye drops, Lumify redness reliever eye drops (brimonidine tartrate ophthalmic solution 0.025%, Bausch + Lomb) and Besivance 0.6% (besifloxacin ophthalmic suspension, Bausch + Lomb), for in vitro antiviral activity using a Vero E-6 host-cell system. Researchers conducted time kill testing of SARS-CoV-2 cultures by multiple dosing followed by solution neutralization; they incubated samples for 4 to 9 days and scored the samples on the presence of residual viable virus.
Study results showed log10 reductions for Lumify and Besivance at the 8-hour contact time (1.8, Lumify), 24-hour contact time (2.14 vs. 1.95, respectively) and 72-hour contact time (2.02 vs. 2.56, respectively).
“Our team presented investigational data that evaluated the in vitro antiviral activity of Lumify and Besivance against SARS-CoV-2, and the results indicated complete inactivation of the virus,” Joseph C. Papa, Bausch Health chairman and CEO, said in the release. “The clinical relevance of these in vitro data are not known, and our intention is to further review these data to determine next steps, including potential discussions with regulatory agencies around the world.”
Neither Lumify nor Besivance have been proven to prevent or treat COVID-19, according to the release.
Read more about
Click Here to Manage Email Alerts